Aptabio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 41

Employees

  • Stock Symbol
  • 293780

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.37
  • (As of Friday Closing)

Aptabio General Information

Description

Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Contact Information

Website
www.aptabio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Heungdeok IT Valley, 13
  • Heungdeok 1-ro, Giheung-gu
  • Yongin, Gyeonggi
  • South Korea
+82
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
KRX
Corporate Office
  • Heungdeok IT Valley, 13
  • Heungdeok 1-ro, Giheung-gu
  • Yongin, Gyeonggi
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aptabio Stock Performance

As of 13-Nov-2026, Aptabio’s stock price is $3.37. Its current market cap is $94.6M with 28.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.37 $3.49 $2.50 - $7.40 $94.6M 28.1M 61.7K -$0.37

Aptabio Financials Summary

As of 30-Jun-2026, Aptabio has a trailing 12-month revenue of $3.28M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 81,224 167,309 90,346 117,880
Revenue 3,275 2,598 2,463 248
EBITDA (8,557) (9,643) (18,970) (11,438)
Net Income (10,246) (11,486) (21,531) (9,225)
Total Assets 35,253 41,685 52,570 71,794
Total Debt 3,184 3,071 5,106 10,813
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aptabio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aptabio‘s full profile, request access.

Request a free trial

Aptabio Patents

Aptabio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026230945-A1 Composition comprising pyrazole derivative for treating ocular diseases Pending 29-Apr-2025
WO-2026221354-A1 Pharmaceutical composition for preventing or treating bcl-2 family inhibitor-resistant acute myeloid leukemia Pending 16-Apr-2025
WO-2026014993-A1 Composition comprising pyrazole derivative for treating cancer Pending 12-Jul-2024
EP-4501920-A1 Novel pyrazole derivatives Inactive 31-Mar-2022
JP-2025514621-A Novel pyrazole derivatives Inactive 31-Mar-2022 A61P35/00
To view Aptabio’s complete patent history, request access »

Aptabio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aptabio Investments & Acquisitions (2)

Aptabio’s most recent deal was a Merger/Acquisition with likalika. The deal was made on 01-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
likalika 01-Jan-2025 Merger/Acquisition Other Consumer Durables
FMW 23-Jul-2024 Corporate Food Products
To view Aptabio’s complete investments and acquisitions history, request access »

Aptabio ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

41.27 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,669

Rank

Percentile

Pharmaceuticals

Industry

of 895

Rank

Percentile

Pharmaceuticals

Subindustry

of 431

Rank

Percentile

To view Aptabio’s complete esg history, request access »

Aptabio Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
likalika Seoul, South Korea 2019

Aptabio FAQs

  • When was Aptabio founded?

    Aptabio was founded in 2009.

  • Where is Aptabio headquartered?

    Aptabio is headquartered in Yongin, South Korea.

  • What is the size of Aptabio?

    Aptabio has 41 total employees.

  • What industry is Aptabio in?

    Aptabio’s primary industry is Pharmaceuticals.

  • Is Aptabio a private or public company?

    Aptabio is a Public company.

  • What is Aptabio’s stock symbol?

    The ticker symbol for Aptabio is 293780.

  • What is the current stock price of Aptabio?

    As of 13-Nov-2026 the stock price of Aptabio is $3.37.

  • What is the current market cap of Aptabio?

    The current market capitalization of Aptabio is $94.6M.

  • What is Aptabio’s current revenue?

    The trailing twelve month revenue for Aptabio is $3.28M.

  • What is Aptabio’s annual earnings per share (EPS)?

    Aptabio’s EPS for 12 months was -$0.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process